Author Login

Correspondence to Author: Anu Kumari¹Phd, Dr. Anupriya Kaur²,Charanpreet Singh³, Dr. Anju Goyal⁴, Dr. Priyanka Srivastava⁵, Dr. Arihant Jain⁶, Dr. Sreejesh Sreedharanunni⁷, Dr. Amanjit Bal⁸, Dr. Alka Rani Khadwal⁹,Dr. Pankaj Malhotra¹⁰. 

1. Department of Clinical Hematology & Medical oncology, PGIMER, Chandigarh. Email: anu1995gn@gmail.com
2. (Associate Professor), Genetics & Metabolic Unit, Advanced Pediatric Centre, PGIMER, Chandigarh. Email: anukaur.genetics@gmail.com
3. Department of Clinical Hematology & Medical oncology, PGIMER, Chandigarh. Email: charanpreetsingh14@gmail.com
4. Assistant Professor, Department of statistics, Panjab University, Chandigarh. Email: anju.statistics@gmail.com
5. Assistant Professor, Genetics & Metabolic Unit, Advanced Pediatric Centre, PGIMER, Chandigarh. Email: srivastavapriy@gmail.com
6. (Associate Professor), Department of Clinical Hematology & Medical Oncology, PGIMER, Chandigarh, Email: drarihantjain86@gmail.com
7. Additional Professor , Department of Hematology, PGIMER, Chandigarh, Email: dr.s.sreejesh@gmail.com
8. Professor, Department of Histopathology, PGIMER, Chandigarh, Email: docaman6@gmail.com
9. (Professor), Department of Clinical Hematology & Medical Oncology, PGIMER, Chandigarh, Email: alkakhadwal@hotmail.com
10. Professor & HOD, Department of Clinical Hematology & Medical Oncology, PGIMER, Chandigarh, Email: malhotrapankaj@hotmail.com

DOI: 10.52338/tejoc.2025.4773

Abstract:

Circulating cell-free DNA (ccf-DNA) and circulating tumor DNA (ctDNA) provide a minimally invasive method for cancer detection and measurement. However, their diagnostic and prognostic significance in hematological malignancies remains ambiguous. This meta-analysis aims to evaluate the prognostic value of ccf-DNA or ctDNA in patients with diffuse large B-cell lymphoma (DLBCL). All relevant literature was retrieved through a systematic search of electronic databases, including PubMed, Embase, Scopus, and the Cochrane Library. Eight eligible studies were selected for the analysis of prognostic value of ccf-DNA or ctDNA. Statistical analyses were performed using R software. The results indicate significant associations with both PFS (HR = 2.14; 95% CI: 1.31–3.40; p < 0.01) and OS (HR = 2.51; 95% CI: 1.84–3.40) for patients with elevated ccf-DNA or ctDNA levels. The results of this meta-analysis strongly suggest that elevated levels of ccfDNA or ctDNA are indicative of poor prognosis in patients with DLBCL.

Keywords:Circulating cell-free DNA , circulating tumor DNA , DLBCL, Prognosis, Hazard Ratio, Meta-analysis.

Citation:

Gaurav Prakash, Prognostic Value of Circulating Tumor DNA (ctDNA) in Diffuse Large B-Cell Lymphoma (DLBCL): Systemic Review and Meta-Analysis. The European Journal of Cancer 2025.